Management of Syphilis in the HIV-infected Patient: Facts and Controversies
Overview
Authors
Affiliations
After reaching an all time low at the turn of the millennium in several industrialized countries, the syphilis incidence is rising again, perhaps as a consequence of unsafe sexual behavior in response to improved antiretroviral therapeutic options for HIV. Since the beginning of the HIV pandemic, numerous reports on the various aspects of the interaction between syphilis and HIV have been published. Controversies persist on many issues of the management of coinfected patients. This contribution presents a critical appraisal of the available literature. Few large-scale, properly designed, controlled studies have compared syphilis baseline presentation and treatment response according to HIV status. Among the weakness are (1) high rates of patients lost to follow-up, (2) lack of long-term follow-up, (3) lack of gold standard criteria for treatment response, (4) small sample size, and (5) lack of stratification according to syphilis stage, ongoing antiretroviral treatment, CD4 cell count and HIV viral load. From the available data, and given the ever-possible publication bias, we conclude that if HIV has an effect on the course of syphilis, it is small and clinically manageable in most cases. The controversial issues discussed should furnish the rational for clinical research during the forthcoming decade.
Neurosyphilis: insights into its pathogenesis, susceptibility, diagnosis, treatment, and prevention.
Wu S, Ye F, Wang Y, Li D Front Neurol. 2024; 14:1340321.
PMID: 38274871 PMC: 10808744. DOI: 10.3389/fneur.2023.1340321.
Investigating latent syphilis in HIV treatment-experienced Ethiopians and response to therapy.
Girma S, Amogne W PLoS One. 2022; 17(7):e0270878.
PMID: 35819944 PMC: 9275702. DOI: 10.1371/journal.pone.0270878.
Yu J, Shi J, Wan H, Li J, Shao Y, Ye J Medicine (Baltimore). 2021; 100(42):e27430.
PMID: 34678871 PMC: 8542171. DOI: 10.1097/MD.0000000000027430.
The Intersection of HIV and Syphilis: Update on the Key Considerations in Testing and Management.
Ren M, Dashwood T, Walmsley S Curr HIV/AIDS Rep. 2021; 18(4):280-288.
PMID: 34091858 PMC: 8180186. DOI: 10.1007/s11904-021-00564-z.
Sogkas G, Ernst D, Atschekzei F, Jablonka A, Schmidt R, Behrens G Infect Dis Ther. 2018; 7(4):485-494.
PMID: 30377976 PMC: 6249181. DOI: 10.1007/s40121-018-0219-9.